IGF-1, LR3
€25 per 10μg
€69 per 5x10μg
€50 per 50μg
€75 per 10x10μg
€70 per 100μg
€210 per 500(5x100)μg
€210 per 10x100μg
€200 per 1000μg
€420 per 20x100320μg
€320 per 2x1000μg
€300 per 2000μg
€1.050 per 50x100μg
€800 per 5x1000μg
€775 per 5000μg
IK0300
Description
The IGFs are mitogenic, polypeptide growth factors that stimulate the proliferation and survival of various cell types, including muscle, bone, and cartilage tissue in vitro. IGFs are predominantly produced by the liver, although a variety of tissues produce the IGFs at distinctive times. The IGFs belong to the Insulin gene family, which also contains insulin and relaxin. The IGFs are similar to insulin by structure and function but have a much higher growth-promoting activity than insulin. IGF-1 LR3 is a recombinant analog of human IGF-1 comprised of the complete IGF-1 sequence, with an Arginine substitution for the third position Glutamic acid, and a 13 amino acid length N terminus peptide extension. Specifically engineered for higher biological potency in vitro, IGF-1 LR3 has an increased half-life and a binding aversion to native proteins within the body that make it ideal for both research and large-scale culturing.
Source
Produced in the endosperm tissue of barley grain (Hordeum vulgare).
Formulation
PBS pH 7.2, sterile filtered through 0.2 µm filter
Purity
Greater than 95% by SDS-PAGE gel analysis.
Reconstitution
Note: Always centrifuge the vial before opening. It is recommended to reconstitute the lyophilized protein in sterile buffered saline to a concentration of no less than 100 µg/ml. For long term storage of the recon statute solution it is recommended to add a carrier protein (0.1% HSA or BSA).
Stability
The lyophilized protein, though stable at room temperature for few weeks, is best stored at -20°C. Reconstituted protein should be used immediately or stored in working aliquots at -20°C. Avoid repeated freeze-thaw cycles.
Biological Activity
The bioactivity of ISOkine® recombinant human IGF-1, LR3 is assayed by measuring its dose dependent effect on proliferation of FDC-P1 cells.
The ED50 for this effect using IGF-1, LR3 is < 2 ng/ml, corresponding to a specific activity >0,5 10 x10e6 U/mg.
We recommend that the optimal concentration for each specific application be determined by an initial dose-response assay. Each batch of ISOkine® growth factor is tested for bioactivity and verified to have comparable activity to a commercial source.
Endotoxin Level
Endotoxin level is less than 0.005ng per µg of ISOkine® product (0.05EU/µg).
MAT Assay
Purified ISOkine® product carries no pyrogenic or pro-inflammatory contaminants, as assayed with monocyte activation test using Human 10-plex Cytokine Assay measuring IL-6, TNF alpha and IL-1beta induction. ** Ref. The Blood Bank, University Hospital of Iceland, Reykjavik, Iceland
Molecular Weight
Recombinant human ISOkine®IGF-1 LR3 is a 9,1 kDa, single, non-glycosylated polypeptide chain containing 83 amino acid residues and a 16 a.a. Histidine-based tag for a total length of 99 a.a The recombinant protein migrates with an apparent molecular mass of 12.5 kDa in SDS-PAGE.